MIRA
MIRA Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$0.76
+3.27%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 2.1M | 1.7M | 3.3M | 1.6M | 2.4M |
| SG&A Expense | 7.3M | 8.8M | 4.7M | 6.5M | 3.0M |
| General & Admin Expense | 7.3M | 8.8M | 4.7M | 6.5M | 3.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | 453.6K | 1.7M |
| Total Operating Expenses | 9.4M | 10.5M | 8.0M | 8.5M | 7.0M |
| Cost and Expenses | 9.4M | 10.5M | 8.0M | 8.5M | 7.0M |
| Operating Income (EBIT) | (9.4M) | (10.5M) | (8.0M) | (8.5M) | (7.0M) |
| Non-Operating | |||||
| Interest Income | 149.0K | 98.9K | — | — | — |
| Interest Expense | — | — | 165.7K | 3.5M | 10.3K |
| Net Interest Income | 149.0K | 98.9K | (165.7K) | (3.5M) | (10.3K) |
| Other Non-Op Income/Expense | (78.3K) | 50.6K | 165.7K | (3.5M) | (10.3K) |
| Non-Operating Income (excl Interest) | 25.9K | (50.6K) | (0.00) | — | — |
| EBT (Pre-Tax Income) | (9.5M) | (10.4M) | (7.9M) | (12.0M) | (7.1M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (9.5M) | (10.4M) | (7.9M) | (12.0M) | (7.1M) |
| Earnings from Cont. Ops | (9.5M) | (10.4M) | (7.9M) | (12.0M) | (7.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (31.0M) | (32.0M) | (7.9M) | (12.0M) | (7.1M) |
| Per Share | |||||
| Basic EPS | ($1.38) | ($1.35) | ($0.51) | ($0.65) | ($0.48) |
| Diluted EPS | ($1.38) | ($1.35) | ($0.51) | ($0.65) | ($0.48) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 42.0M | 23.7M | 15.4M | 18.6M | 14.7M |
| Diluted Shares Outstanding | 42.0M | 23.7M | 15.4M | 18.6M | 14.7M |
| Profitability Metrics | |||||
| EBITDA | (9.4M) | (10.4M) | (8.0M) | (8.5M) | — |
| D&A | — | — | — | — | 7.0M |
| EBIT | (9.4M) | (10.4M) | (8.0M) | (8.5M) | (7.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026